NEW YORK (GenomeWeb News) – UK biotech firm Epistem said today that it has received €1.5 million ($2 million) from the European Commission to develop point-of-care diagnostic tests for Hepatitis C as part of a €6 million, international project called the PoC HCV consortium.

The consortium aims to develop integrated genetic and protein biomarker tests for use in treating and monitoring HCV patients, as well as in clinical research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.

Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.